Skip to search formSkip to main contentSkip to account menu

gimeracil

Known as: 5-Chloro-2,4-pyridinediol, 5-chloro-2,4-dihydroxypyridine, CDHP 
A pyridine derivative with antitumor activity. Gimeracil enhances the antitumor activity of fluoropyrimidines by competitively and reversibly… 
National Institutes of Health

Related topics

Related topics

3 relations
NCIt Antineoplastic Agent Terminology

Broader (2)

Pyridineschlorodihydroxypyridine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur–gimeracil–oteracil potassium in metastatic and recurrent breast cancer
BackgroundWe investigated the efficacy and safety of metronomic chemotherapy with combined irinotecan and tegafur–gimeracil… 
2014
2014
Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus.
2012
2012
Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer
BackgroundIn this phase II clinical trial, we evaluated the efficacy and safety of S-1 monotherapy in patients with previously… 
2009
2009
The role of dihydropyrimidine dehydrogenase expression in resistance to 5-fluorouracil in head and neck squamous cell carcinoma cells.
2006
2006
Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer
PurposeS-1 is a novel oral fluoropyrimidine that combines tegafur with CDHP and oxonic acid. To decrease the incidence of late… 
2006
2006
Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1
The effect of gastrectomy on pharmacokinetics after S-1 administration was investigated in a total of 12 cases – nine in which… 
2006
2006
A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
BACKGROUND S-1 is a novel oral fluorouracil antitumor drug that contains a combination of 3 pharmacological agents: tegafur (FT… 
2006
2006
Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil
Abstract S-1 is an oral formulation combining tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate (Oxo) in… 
2002
2002
Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
PURPOSE To determine the maximum tolerated dose, dose-limiting toxicities(DLTs), and pharmacokinetics of S-1, a combination of… 
2002
2002
Increased Intestinal Permeability Correlates with Gastrointestinal Toxicity among Formulations of the Fluorouracil Analogue Tegafur in Rats
Background: S-1 is a new antitumor agent which was developed based on biochemical modulation of fluorouracil. S-1 consists of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)